Cerity Partners
MYGN icon

Cerity Partners’s Myriad Genetics MYGN Stock Holding History

Cerity Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Sell
65,835
-8,146
-11% -$37K ﹤0.01% 2629
2026
Q1 		$333K Sell
73,981
-12,494
-14% -$65.1K ﹤0.01% 2539
2025
Q4 		$532K Buy
86,475
+6,923
+9% +$50.2K ﹤0.01% 2069
2025
Q3 		$575K Buy
79,552
+57,121
+255% +$339K ﹤0.01% 1886
2025
Q2 		$119K Buy
+22,431
New +$132K ﹤0.01% 2452

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cerity Partners's MYGN Position: Q2 2026 in Review

Cerity Partners reduced its Myriad Genetics (MYGN) stake by 11% in Q2 2026, selling an estimated $37K and leaving 65,835 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Cerity Partners first reported a position in MYGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $575K in Q3 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Cerity Partners held 65,835 shares of Myriad Genetics worth $376K as of Q2 2026.
  • Cerity Partners sold 8,146 Myriad Genetics shares in Q2 2026, an estimated $37K.
  • Myriad Genetics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2629 holding.
  • Cerity Partners first reported a position in Myriad Genetics in Q2 2025 and has held it in 5 quarters since.
  • Cerity Partners's Myriad Genetics position peaked at $575K in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.